| Drug ID: | Drug181 |
|---|---|
| Drug Name: | Steroids |
| CID: | 139082353 |
| DrugBank ID: | NULL |
| Modality: | Small Molecule |
| Groups: | NULL |
| US Approved: | NULL |
| Other Approved: | NULL |
| Identifier: | NCT05702879, , NCT03460847 |
| Molecular Formula: | C26H44N2O |
| Molecular Weight: | 400.6 g/mol |
| Isomeric SMILES: | C[C@H]([C@@H]1CC[C@H]2[C@]1(CC[C@@H]3[C@@H]2CC=C4[C@]3(CC[C@@H](C4)N(C)C)C)C)N(C)C(=O)C |
| Synonyms: | Steroid; 3alpha-Dimethylamino-20-(N-methylacetamido)pregn-5-ene; Steroids; Steroid Compound; Arnolds, Gear, Gym Candy, Juice, Pumpers, Roids, Stackers, Weight Gainers |
| Phase 0: | 0 |
| Phase 1: | 0 |
| Phase 2: | 0 |
| Phase 3: | 0 |
| Phase 4: | 0 |
| Description: | NULL |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt1299 | 139082353 | Steroids | 1576 | CYP3A4 | Homo sapiens (human) | 15955870 | Steroids results in increased expression of CYP3A4 |
| dt1300 | 139082353 | Steroids | 2554 | GABRA1 | Rattus norvegicus (Norway rat) | 18275132 | GABRA1 protein mutant form results in decreased susceptibility to steroids analog|steroids analog promotes the reaction [gamma-aminobutyric acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]] |
| dt1301 | 139082353 | Steroids | 2561 | GABRB2 | Rattus norvegicus (Norway rat) | 18275132 | Steroids analog promotes the reaction [gamma-aminobutyric acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]] |
| dt1302 | 139082353 | Steroids | 2566 | GABRG2 | Rattus norvegicus (Norway rat) | 18275132 | Steroids analog promotes the reaction [gamma-aminobutyric acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]] |
| dt1303 | 139082353 | Steroids | 3565 | IL4 | Rattus norvegicus (Norway rat) | 10685002 | Steroids results in decreased expression of IL4 protein |
| dt1304 | 139082353 | Steroids | 5069 | PAPPA | Mus musculus (house mouse) | 20130263 | PAPPA protein affects the chemical synthesis of steroids |
| dt1305 | 139082353 | Steroids | 5443 | POMC | Rattus norvegicus (Norway rat) | 20021565 | POMC protein affects the reaction [ethanol results in increased abundance of steroids] |
| dt1306 | 139082353 | Steroids | 5443 | POMC | Rattus norvegicus (Norway rat) | 1668613 | POMC protein alternative form affects the abundance of steroids |
| dt1307 | 139082353 | Steroids | 103142 | Rdh9 | Mus musculus (house mouse) | 17270348 | RDH9 protein results in increased metabolism of steroids |
| dt1308 | 139082353 | Steroids | 6770 | STAR | Rattus norvegicus (Norway rat) | 12699903 | [manganese chloride results in decreased expression of STAR protein] which results in decreased chemical synthesis of steroids |
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT05702879 | Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success | NULL | UNKNOWN | Insel Gruppe AG, University Hospital Bern | Ulcerative Colitis | DRUG: Ozanimod|DRUG: TNF Inhibitor|DRUG: Steroids… | Details |
| NCT05284136 | Exclusion Diet vs corticosteroIds in patientS With activE Crohn's Disease | PHASE2|PHASE3 | UNKNOWN | Assistance Publique - Hôpitaux de Paris | Crohn Disease | DIETARY_SUPPLEMENT: Crohn's disease exclusion die… | Details |
| NCT04999228 | Top Down Versus Step up in Pediatric Ulcerative Colitis | PHASE4 | RECRUITING | Children's Hospital of Fudan University | Ulcerative Colitis|Infliximab|Children | DRUG: Infliximab|DRUG: Corticosteroids | Details |
| NCT04564638 | Long-term Outcome of Patients With Acute Ulcerative Colitis After First Course of Intravenous Corticosteroids | NULL | COMPLETED | Tampere University Hospital | Ulcerative Colitis | DRUG: Corticosteroid | Details |
| NCT03942861 | Sonographic Assessment in Severe Ulcerative Colitis Patients Admitted for Intravenous Corticosteroids and Eligible for Infliximab Rescue Therapy; a Prospective Clinician-blinded Observational Study Protocol. | NULL | UNKNOWN | Copenhagen University Hospital at Herlev | Ulcerative Colitis|Ultrasound Therapy; Complicati… | DRUG: Solu-Medrol | Details |
| NCT03833596 | Exclusive Enteral Nutrition and Corticosteroids Therapy in Crohn's Disease (EENCD) | PHASE4 | TERMINATED | McMaster University | Crohn's Disease | DRUG: Prednisone|DIETARY_SUPPLEMENT: Exclusive En… | Details |
| NCT03460847 | Fecal Microbiota Alterations in Steroid Refractory Active Colitis Ulcerosa | NULL | COMPLETED | Medical University of Graz | Colitis, Ulcerative | DRUG: Steroids | Details |
| NCT02922374 | Ulcerative Colitis Endoscopic Index of Severity and Fecal Calprotectin to Predict the Reaction to Corticosteroids of Acute Severe Ulcerative Colitis | PHASE1|PHASE2 | UNKNOWN | Jinling Hospital, China | Acute Severe Colitis (ASC) | DRUG: corticosteroids | Details |
| NCT02665845 | Combination Corticosteroids+5-aminosalicylic Acids Compared to Corticosteroids Alone (for Ulcerative Colitis). | PHASE3 | COMPLETED | Centre Hospitalier Universitaire de Saint Etienne | Ulcerative Colitis | DRUG: 5-ASA|DRUG: Corticosteroids | Details |
| NCT02619552 | Impact of Medical Treatment on Sexual Function in Patients With Crohn's Disease | NULL | COMPLETED | University of Maryland, Baltimore | Crohn's Disease|IBD | DRUG: Anti-TNF|DRUG: Anti-TNF|DRUG: Steroids | Details |
| NCT02425852 | A Randomized, Multicenter Open Label Study Comparing Early Administration of Azathioprine Plus IFX to Steroids Plus Azathioprine for Acute Severe Colitis | PHASE4 | COMPLETED | Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives | Ulcerative Colitis | DRUG: Azathioprine|DRUG: Infliximab|DRUG: Prednis… | Details |
| NCT02324699 | Corticosteroids With Vedolizumab in Crohn's Disease | PHASE4 | TERMINATED | Icahn School of Medicine at Mount Sinai | Crohn's Disease | DRUG: Prednisone|DRUG: Placebo|DRUG: Vedolizumab | Details |
| NCT02033408 | Manipulating the Microbiome in IBD by Antibiotics and FMT | NA | COMPLETED | Shaare Zedek Medical Center | Exacerbation of Ulcerative Colitis|Ulcerative Col… | DRUG: AB (antibiotics)|DRUG: CS (corticosteroids)… | Details |
| NCT01941589 | Corticosteroids+5-aminosalicylic Acid Compared to Corticosteroids in the Treatment of Moderate-severe Ulcerative Colitis | PHASE4 | COMPLETED | Sheba Medical Center | Ulcerative Colitis | DRUG: oral 5-ASA+/-topical 5-ASA+IV corticosteroi… | Details |
| NCT01536535 | Predicting Response to Standardized Pediatric Colitis Therapy | PHASE4 | COMPLETED | Connecticut Children's Medical Center | Ulcerative Colitis | DRUG: Mesalazine|DRUG: IV Corticosteroid|DRUG: Or… | Details |
| NCT00702611 | Efficacy Study of Granulocytapheresis Plus Steroids vs Steroids Alone in Active Steroid Dependant Ulcerative Colitis | PHASE4 | TERMINATED | Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa | Ulcerative Colitis | DEVICE: Granulocyte Monocyte Apheresis (GMA-Apher… | Details |
| NCT00672763 | Adjuvant Vitamin D With Corticosteroids in Active Crohn's Disease | PHASE4 | WITHDRAWN | Imperial College London | Crohn's Disease | DRUG: Colecalciferol D3 (Vigantol Oil)|DRUG: Medi… | Details |
| NCT00514982 | Medical Treatment of Colitis in Patients With Hermansky-Pudlak Syndrome | PHASE2 | WITHDRAWN | National Institute of Allergy and Infectious Diseases (NIAID) | Hermanski-Pudlak Syndrome|Colitis|Cytokines|Lymph… | DRUG: Mesalamine|DRUG: Infliximab|DRUG: Corticost… | Details |
| NCT00269438 | New Tablet Formulation and Dosing Regimen of Balsalazide Disodium in Mildly to Moderately Active Ulcerative Colitis | PHASE3 | COMPLETED | Bausch Health Americas, Inc. | Ulcerative Colitis | DRUG: 5 ASA, enemas, suppositories, corticosteroi… | Details |
| NCT00265772 | Comparison of a Nutritional Anti-Inflammatory Treatment to Steroids for Pediatric Crohn's Disease - the Molecular Basis | PHASE4 | UNKNOWN | Hôpital Necker-Enfants Malades | Crohn's Disease|Pediatric | DRUG: MODULEN IBD (R) (specific Enteral Nutrition… | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| S01 | Anti-inflammatory | inflammatory | 5-Aminosalicylates (5-ASAs); corticosteroids | Crohn's disease and ulcerative colitis are the two main com… | Details |
Appropriate use and complications of corticosteroids in inflammatory bowel dise…
PMID: 40588110
Year: 2025
Relationship Type:
Adverse Effect
Score: 10.0
Corticosteroids are one of the most frequently prescribed medications for the management of inflammatory bowel disease. While corticosteroids have a …
Comorbidities and systemic steroids drive pneumonia risk in inflammatory bowel …
PMID: 40575363
Year: 2025
Relationship Type:
Association
Score: 10.0
BACKGROUND: Patients with inflammatory bowel disease (IBD) are at an increased risk of bacterial pneumonia, contributing to significant morbidity and…
Cardiotonic Steroids as a Potential Novel Approach for Immunomodulation in Infl…
PMID: 40565877
Year: 2025
Relationship Type:
Treatment
Score: 10.0
Inflammatory bowel disease (IBD) is a chronic condition that significantly impairs the quality of life of millions of individuals. The pathogenesis o…
An International Consensus on Appropriate Management of Corticosteroids in Clin…
PMID: 40446946
Year: 2025
Relationship Type:
Treatment
Score: 10.0
BACKGROUND & AIMS: Approval of new therapies for inflammatory bowel disease (IBD) requires rigorously designed and well-executed randomized controlle…
Top-down infliximab plus azathioprine versus azathioprine alone in patients wit…
PMID: 39586616
Year: 2025
Relationship Type:
Treatment
Score: 10.0
BACKGROUND: It is unknown which maintenance therapy is the most effective option for patients admitted for an acute severe ulcerative colitis (ASUC) …
Extended Monitoring for Transition to Oral Corticosteroids in Acute Severe Ulce…
PMID: 39495414
Year: 2024
Relationship Type:
Treatment
Score: 10.0
BACKGROUND: There is no guideline regarding whether patients treated with intravenous corticosteroids for acute severe ulcerative colitis (ASUC) shou…
Prescribed cumulative dosage of corticosteroids to patients with inflammatory b…
PMID: 39403301
Year: 2024
Relationship Type:
Treatment
Score: 10.0
BACKGROUND: Treatments and strategies for inflammatory bowel disease (IBD) have gradually evolved in the 2000s. OBJECTIVES: We investigated whether t…
Preterm Birth and in Utero Exposure to Corticosteroids Are Associated With Incr…
PMID: 38206331
Year: 2024
Relationship Type:
Treatment
Score: 10.0
BACKGROUND: Corticosteroids, thiopurines, and biologics may come into play during pregnancy in women with inflammatory bowel disease and potentially …
Anti-tumor Necrosis Factor Alpha Versus Corticosteroids: A 3-fold Difference in…
PMID: 37952112
Year: 2024
Relationship Type:
Treatment
Score: 10.0
BACKGROUND AND AIMS: Patients with inflammatory bowel disease [IBD] have a more than two fold higher risk of venous thromboembolic events [VTE] than …
Therapeutic Potential of BMP7 in the Treatment of Osteoporosis Caused by the In…
PMID: 37626658
Year: 2023
Relationship Type:
Treatment
Score: 10.0
Individuals with inflammatory bowel disease (IBD) have an increased risk of bone impairment, which is a process controlled by the RANKL/RANK/OPG syst…
Corticosteroids but not Anti-TNF Are Associated With Increased COVID-19 Complic…
PMID: 37611117
Year: 2024
Relationship Type:
Treatment
Score: 10.0
BACKGROUND AND AIMS: Immunosuppressed individuals are at higher risk for COVID-19 complications, yet data in patients with inflammatory bowel disease…
Factors Associated with Response to Systemic Corticosteroids in Active Ulcerati…
PMID: 37510968
Year: 2023
Relationship Type:
Treatment
Score: 10.0
BACKGROUND: Among patients with ulcerative colitis, 30-50% receive corticosteroids within the first five years after diagnosis. We aimed to reconside…
Review article: Updated management of acute severe ulcerative colitis: From ste…
PMID: 37475143
Year: 2023
Relationship Type:
Treatment
Score: 10.0
Acute severe ulcerative colitis (ASUC) occurs in up to 25% of patients with ulcerative colitis (UC). Therapeutic approaches have evolved during the p…
Fecal Biomarkers of Neutrophil and Eosinophil Origin Reflect the Response to Bi…
PMID: 37256716
Year: 2023
Relationship Type:
Treatment
Score: 10.0
INTRODUCTION: Fecal calprotectin (FC) is a noninvasive tool for examining response to biologics in inflammatory bowel disease (IBD), but its performa…
A case of nocardiosis in a patient with ulcerative colitis on chronic corticost…
PMID: 37207089
Year: 2023
Relationship Type:
Treatment
Score: 10.0
KEY CLINICAL MESSAGE: Immunosuppression, malnutrition, and underlying infection can unmask obscure infections which can be challenging to identify. E…
Adverse birth outcomes and early-life infections after in utero exposure to cor…
PMID: 37046314
Year: 2023
Relationship Type:
Treatment
Score: 10.0
BACKGROUND: Systemic corticosteroids are often used to treat inflammatory bowel disease (IBD) flares during pregnancy as maintenance of disease remis…
Corticosteroids Increase the Risk of Invasive Fungal Infections More Than Tumor…
PMID: 36911593
Year: 2023
Relationship Type:
Treatment
Score: 10.0
BACKGROUND: Invasive fungal infections are a devastating complication of inflammatory bowel disease (IBD) treatment. We aimed to determine the incide…
Microbiota signatures and mucosal healing in the use of enteral nutrition thera…
PMID: 36788671
Year: 2023
Relationship Type:
Treatment
Score: 10.0
Corticosteroids (CS) and exclusive and partial enteral nutrition (EEN and PEN) are effective therapies in paediatric Crohn's disease (CD). This syste…
Impact of Concomitant Corticosteroids on Tofacitinib Induction Efficacy and Inf…
PMID: 36739367
Year: 2023
Relationship Type:
Treatment
Score: 10.0
BACKGROUND: Tofacitinib is an oral small molecule Janus kinase inhibitor for the treatment of ulcerative colitis. AIM: To report efficacy and infecti…
Corticosteroids in inflammatory bowel disease: Are they still a therapeutic opt…
PMID: 36375697
Year: 2023
Relationship Type:
Treatment
Score: 10.0
Despite the development and incorporation of new therapeutic strategies, such as biologic therapy and small molecules, corticosteroids still play an …